Potential risks and pharmacological safety features of hypoglycemic drugs

Показати скорочений опис матеріалу

dc.contributor.author Drogovoz, S. en
dc.contributor.author Kalko, K. en
dc.contributor.author Borysiuk, I. en
dc.contributor.author Barus, M. en
dc.contributor.author Horoshko, V. en
dc.contributor.author Svyshch, O. en
dc.contributor.author Liulchak, S. en
dc.date.accessioned 2023-01-31T10:19:43Z
dc.date.available 2023-01-31T10:19:43Z
dc.date.issued 2021
dc.identifier.citation Potential risks and pharmacological safety features of hypoglycemic drugs / S. Drogovoz, K. Kalko, I. Borysiuk et al. // PhOL. 2021. Vol. 2. P. 1164-1171. en
dc.identifier.uri https://repo.odmu.edu.ua:443/xmlui/handle/123456789/12038
dc.description.abstract For the treatment of diabetes, insulin preparations, synthetic hypoglycemic agents, herbal medicine and compulsory adherence to the diet. Oral hypoglycemic agents belong to different chemical classes: sulfonylurea derivatives, biguanides, thiazolidinediones, etc. They can also be divided into secretogens (stimulate pancreatic insulin secretion, especially in the presence of glucose) and prandial (food - related) glycemic regulators (lower glucose in the blood after eating). As for the pharmacological safety of oral antidiabetic agents, they are incompatible with adrenal cortex hormones, adrenomimetics, MAO inhibitors, psychostimulants, antiarrhythmic agents. Their hypoglycemic effect is weakened by estrogens, gestagens, oral contraceptives, chlorpromazine, barbiturates, phenothiazines, thyroid hormones, glucagon, lithium salts, saluretics, indomethacin, drugs containing nicotinic acid. en
dc.language.iso en en
dc.subject hypoglycemic drugs en
dc.subject potential risks en
dc.subject pharmacological safety en
dc.title Potential risks and pharmacological safety features of hypoglycemic drugs en
dc.type Article en


Долучені файли

Даний матеріал зустрічається у наступних зібраннях

Показати скорочений опис матеріалу